These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 21817083

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
    Brunetti L, Poustchi S, Cunningham D, Toscani M, Nguyen J, Lim J, Ding Y, Nahass RG.
    Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M, Buurma V, Shah M, Fahim G.
    Am J Health Syst Pharm; 2019 Sep 03; 76(18):1383-1394. PubMed ID: 31505562
    [Abstract] [Full Text] [Related]

  • 4. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
    Lodise TP, Lomaestro B, Drusano GL.
    Clin Infect Dis; 2007 Feb 01; 44(3):357-63. PubMed ID: 17205441
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H, Lv Y, Wang D, Xue J, Yan Z.
    Eur J Clin Microbiol Infect Dis; 2017 Mar 01; 36(3):459-466. PubMed ID: 27796647
    [Abstract] [Full Text] [Related]

  • 6. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
    Fan SY, Shum HP, Cheng WY, Chan YH, Leung SM, Yan WW.
    Pharmacotherapy; 2017 Jan 01; 37(1):109-119. PubMed ID: 27888542
    [Abstract] [Full Text] [Related]

  • 7. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ, Cappelletty DM, RECEIPT Study group.
    Pharmacotherapy; 2011 Aug 01; 31(8):767-75. PubMed ID: 21923603
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
    Attivi D, Gibaud S.
    Ann Pharm Fr; 2014 May 01; 72(3):146-51. PubMed ID: 24780830
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, Savoie M, Fagnan M, Amyot J, Tétreault N, Robitaille R, Varin F, Lavallée C, Pichette V, Leblanc M.
    Pharmacotherapy; 2015 Jun 01; 35(6):600-7. PubMed ID: 26095008
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa.
    Zelenitsky S, Nash J, Weber Z, Iacovides H, Ariano R.
    J Chemother; 2016 Oct 01; 28(5):390-4. PubMed ID: 27077931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.